Afrezza plus One Drop | Premium
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Oct 5, 2017 → Dec 30, 2019
NCT ID
NCT03313960About Afrezza plus One Drop | Premium
Afrezza plus One Drop | Premium is a approved stage product being developed by MannKind Corp for Diabetes Mellitus, Type 2. The current trial status is unknown. This product is registered under clinical trial identifier NCT03313960. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03313960 | Approved | UNKNOWN |
Competing Products
20 competing products in Diabetes Mellitus, Type 2
Other Products from MannKind Corp
Technosphere insulinApproved
80
Afrezza + insulin degludec + Rapid-acting Insulin Analog + Basal InsulinApproved
80
Afrezza (insulin human) Inhalation Powder + insulin degludecApproved
80
Technosphere® Insulin with MedTone C Inhaler + Technosphere ®Insulin with Gen2 Inhaler + Insulin Aspart in combination with a basal insulinPhase 3
72
Technosphere® Insulin + Technosphere PowderPhase 3
72